Immutep sees first patient dosed in 4th arm of cancer trial

Company News

by Rachael Jones

Biotech company Immutep (ASX:IMM) reports that the first patient in the INSIGHT-004 Phase I clinical trial has received the first dose of treatment in Germany.

INSIGHT-004 is the 4th arm of the INSIGHT trial is being conducted in collaboration with Merck, Darmstadt, Germany and Pfizer Inc.

The study evaluates the safety, tolerability and recommended Phase II dose of Immutep’s lead immunotherapy product candidate efti-lagimod alpha (“efti” or “IMP321”) when administered in combination with avelu-mab (BAVENCIO®) in 12 patients with advanced solid malignancies.

Shares in Immutep (ASX:IMM)
 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.